Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells

The overexpression or amplification of HER2 has been observed in a significant proportion of both gastric cancer (GC) and breast cancer (BC) cases. Pyrotinib is an irreversible dual (EGFR/HER2) tyrosine kinase inhibitor (TKI), newly evaluated for the treatment of HER2-overexpressing cancer types. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Tingting, Luo, Xiaoxiao, Wu, Bili, Peng, Ping, Dai, Yuhong, Hu, Guangyuan, Qiu, Hong, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640366/
https://www.ncbi.nlm.nih.gov/pubmed/33125154
http://dx.doi.org/10.3892/or.2020.7820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640366/
https://www.ncbi.nlm.nih.gov/pubmed/33125154
http://dx.doi.org/10.3892/or.2020.7820

Ejemplares similares